CRISPR biotech Intellia cuts staff as it eyes 2027 launch
pharmaphorum
JANUARY 10, 2025
Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
pharmaphorum
JANUARY 10, 2025
Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
STAT
DECEMBER 12, 2024
The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027. Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
APRIL 25, 2024
Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales of $4 billion by 2027, according to an analyst consensus forecast by GlobalData. Expected revenues in these indications will reach over 68 per cent of the global PARP inhibitors market by 2027.
pharmaphorum
MAY 19, 2023
Teva is eyeing $2.5bn in Austedo sales in 2027 Phil.Taylor Fri, 05/19/2023 - 09:41 Bookmark this
European Pharmaceutical Review
MARCH 27, 2023
percent between 2022 and 2027. Microbiology article: Pharmaceutical microbiology: key developments 2022… The post Rapid microbiology testing market growth expected 2022 to 2027 appeared first on European Pharmaceutical Review. According to the data, the market is forecasted to increase by $2,487.91 Don Whitley Scientific Ltd.,
The Pharmacist
JUNE 11, 2024
The Conservative Party has set out spending plans of £250m each year on Pharmacy First from 2027 to 2030, as it pledges to expand the service to include more conditions like acne and chest infections.
STAT
OCTOBER 26, 2023
About 800,000 nurses plan to leave the workforce by 2027, and more than half of newly graduated nurses are leaving the profession within two years. The Kaiser strike is over, for now, but there is no clear resolution in place, and other strikes are still under way or on the horizon.
STAT
SEPTEMBER 23, 2024
1, and the negotiated prices of those drugs take effect in 2027. Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs. Medicare will announce that list by Feb.
STAT
SEPTEMBER 12, 2024
billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate. Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1
STAT
DECEMBER 13, 2024
The nonprofit Howard Hughes Medical Institute (HHMI) will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for a round of funds to be awarded in 2027.
European Pharmaceutical Review
DECEMBER 9, 2022
billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. billion by 2027 appeared first on European Pharmaceutical Review. The research projected a compound annual growth rate (CAGR) of 16.8 percent from $7.7 billion in 2022.
European Pharmaceutical Review
FEBRUARY 1, 2023
billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29
STAT
JULY 24, 2023
The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.
Express Pharma
NOVEMBER 25, 2024
The Government aims to expand the reach of PMBJP by increasing the number of Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to 25,000 by March 2027. The post Pharmaceuticals & Medical Devices Bureau of India participates in 43rd Edition of IITF 2024 appeared first on Express Pharma.
STAT
JANUARY 17, 2023
The number of health care-related artificial intelligence models on the market has increased steadily over the past decade, with the health care AI market expected to grow from $7 billion today to $67 billion in 2027.
STAT
DECEMBER 7, 2023
One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.
Express Pharma
FEBRUARY 18, 2025
per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3
STAT
OCTOBER 3, 2024
1, 2025, the Centers for Medicare and Medicaid Services will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.
PharmaVoice
JULY 1, 2024
government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027. As the first 10 drugs undergo price negotiations with the U.S.
The Pharmacist
FEBRUARY 20, 2025
No changes will be introduced to the Community Pharmacy England (CPE) committee membership until the current term ends in 2027, notes from the negotiator's latest meeting have confirmed. But the two non-Company Chemists' Association (CCA) 10+ multiple observers will remain as such until March 2027.
Express Pharma
NOVEMBER 5, 2024
million over a three-year period, ending on June 30, 2027, a filing showed. Under terms of the deal, the company and the UKHSA agreed to settle the outstanding amount under dispute related to upfront payments received by Novavax from the health agency. Novavax has agreed to refund $123.8 The first installment payment is due on Nov.
STAT
JUNE 25, 2024
The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.
Pharmaceutical Technology
AUGUST 31, 2023
Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.
STAT
NOVEMBER 20, 2023
Under the new agreement, the level of allowed growth in drug sales will increase from 2% in 2024 to 4% by 2027. The current plan, which has drawn the ire of pharma companies, requires drug companies to pay rebates back to the U.K. if spending on medicines increases by more than 2% a year. Continue to STAT+ to read the full story…
BioPharma Dive
NOVEMBER 15, 2023
The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.
Express Pharma
FEBRUARY 23, 2025
The institution will offer a variety of leadership programmes, ranging from short workshops to extended courses lasting 9 to 12 months, starting in March 2027. SOULs mission is to empower young individuals for roles in public sectors such as health, education, rural development, and sanitation.
Express Pharma
FEBRUARY 11, 2025
billion by 2027, driven by increasing demand for innovative patient-friendly dosage forms, said Paul Smaltz, Head of the Pharmaceutical Solutions Business Unit at Roquette. The platform provides manufacturers with ready-to-use coating premixes for pharmaceutical prescription, nutraceutical, and over-the-counter (OTC) products.
Express Pharma
JANUARY 2, 2025
The late-stage T1D pipeline consists of several agents, including Eli Lillys insulin efsitora alfa, which is anticipated to launch in 2027.
pharmaphorum
FEBRUARY 6, 2025
BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2,200 job cuts, adding a target of another $2bn by end-2027.
Pharmaceutical Commerce
AUGUST 19, 2024
The 86,000 square-foot Køge facility will be fully functional by 2027.
Putting Patients First Blog
JULY 2, 2024
Clarification on QALY Metrics The NHC appreciates CMS’ commitment to excluding Quality-Adjusted Life Years (QALYs) from the negotiation process as outlined in the 2027 draft guidance. Valuing life differently based on disability status, age, or other special populations is inappropriate.
Express Pharma
MARCH 2, 2025
Under PMBJP, the government has set a target to open 25000 JAKs by March 31, 2027 across the country. The product basket of PMBJP comprises 2047 drugs and 300 surgical equipment which are sold at retail shops at 50 per cent to 80 per cent cheaper than branded medicines.
Outsourcing Pharma
OCTOBER 24, 2023
Traditionally, the pharmaceutical landscape has been dominated by small molecules.
The Guardian - Pharmaceutical Industry
SEPTEMBER 21, 2023
The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).
BioPharma Dive
FEBRUARY 6, 2025
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.
PharmaTech
SEPTEMBER 12, 2024
Seventeen biologics and nine tides—five peptides and four oligonucleotides—were approved in 2023 alone, with further growth predicted.
Pharmaceutical Commerce
APRIL 5, 2023
Rise in value attributed to the ongoing decentralization of pharmacies.
STAT
SEPTEMBER 12, 2024
billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. So here are some items of interest. Have a great day, everyone. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1
Pharmacy Times
JANUARY 10, 2023
The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.
Putting Patients First Blog
SEPTEMBER 3, 2024
We strongly urge CMS to address these issues in the IPAY 2027 portal to ensure that all participants, regardless of their familiarity with technology or survey formats, can contribute their insights without unnecessary difficulty. Conclusion The NHC appreciates the opportunity to provide input on the IRA 2027 Drug Price Negotiation ICR.
PharmaTech
OCTOBER 26, 2023
As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.
European Pharmaceutical Review
NOVEMBER 2, 2022
Somewhat ambitious: Meet three percent of GDP by 2027, building on aspirations set out by the Confederation of British Industry (CBI), the European Commission (EC) and opposition political parties. The government would need to invest an extra £1 billion in R&D by 2027. Private investment would also need to rise by £0.8
Pharmaceutical Technology
OCTOBER 6, 2023
Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.
European Pharmaceutical Review
AUGUST 27, 2024
Manufacturing of the biologic products in the expanded Sweden Biomanufacturing Center is planned to begin from Q4 of 2027, according to AstraZeneca. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden”, Alfredsson continued.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content